CVM
Cel-Sci Corp
Stock NYSE – Stock Market Prices, News & Analysis
Cel-Sci Corp focuses on the research and development of immunological therapies to treat cancer and infectious diseases, best known for its experimental treatment Multikine.
Cel-Sci Corp
CVM
Cel-Sci Corp focuses on the research and development of immunological therapies to treat cancer and infectious diseases, best known for its experimental treatment Multikine.
Price history of Cel-Sci Corp
Price history of Cel-Sci Corp
Performance & Momentum
Strategic Analysis
Cel-Sci Corp • 2026
Cel-Sci Corp is positioned in the biotechnology sector, developing innovative immunological therapies for the treatment of cancer and infectious diseases. Its niche is based on its lead therapeutic candidate, Multikine, addressing unmet medical needs with a differentiated immuno-oncology approach.
- Positioning in immunotherapy, a high-potential segment in the fight against cancer.
- Focus on a flagship product with defined clinical applications.
- Presence in the U.S. market, a strategic hub for biotech innovation.
- No commercial validation to date, with an still highly uncertain pipeline.
- Particularly poor long-term stock performance, reflecting operational or investment challenges.
Momentum is extremely weak, marked by a significant erosion in shareholder value across all observed periods. The lack of recent news and high volatility suggest a phase of stagnation or elevated uncertainty, warranting caution for investors seeking a turnaround or acceleration.
Similar stocks to Cel-Sci Corp
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
